SLC5A2 and type 2 diabetes mellitus: Adults with T2DM and a history of polypectomy receiving dual therapy (SGLT-2 inhibitor plus GLP-1 receptor agonist) were compared with SGLT-2 inhibitor monotherapy using 1:1 propensity score matching without replacement.